RxDoctor Payments Data

Aravindhan Arumugarajah, DO

Nephrology · Valparaiso, INNPI 1780978759

Payments from drug & device makers

$1,287in general payments, 2019–2025

Across 55 payments — averaging $23.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vifor Pharma, Inc.$348
  • Travere Therapeutics, Inc.$190
  • Boehringer Ingelheim$152
  • Mallinckrodt Enterprises LLC$130
  • Bayer$117
  • AstraZeneca$116
  • plus $234 from 9 others

What the payments were for

  • Food & beverage$1,14689%
  • Education$14211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,287 in reported general payments places this provider in the 50th percentile of 238 nephrology providers in Indiana.

See all nephrology providers in Indiana

Medicare billing

Part B allowed, 2024
$282,371
Medicare patients
604
Services billed
2,772

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol102$81,238
KerendiaFinerenone81$65,253
JardianceEmpagliflozin81$52,067
XphozahTenapanor Hcl12$34,958
LokelmaSodium Zirconium Cyclosilicate39$14,055
DapagliflozinDapagliflozin Propanediol21$13,481
Potassium Chloride16$2,093
Calcium Acetate11$1,981
Potassium Citrate ErPotassium Citrate16$1,507
Bumetanide28$651
Lisinopril69$383
Furosemide61$274
Cinacalcet Hcl17$254
Midodrine Hcl11$243
Nifedipine ErNifedipine11$216

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$116$95,293141 claims
BayerKerendia$117$65,25381 claims
Boehringer IngelheimJardiance$152$52,06781 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 238 nephrology providers in Indiana.

Other nephrology in Valparaiso

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →